Undoubtedly, a safe, effective medication for obesity would be a pharmaceutical blockbuster. The record so far on previous medications has been dismal. Many have been abandoned due to safety concerns, including sibutramine (myocardial infarction and stroke) as well as dexfenfluramine/fenfluramine (valvulopathy). Two new FDA-approved agents have shown promise but caution in their use will be needed (NEJM 2012; 367: 1577-79). Neither agent has approval for pediatric usage.
Belviq (lorcaserin) is a selective agonist of the serotonin 5-HT-2C receptor and Qsymia (phentermine with topiramate) is a combination sympathomimetic amine (anorectic agent) with an antiepileptic drug.
In studies with lorcaserin, three studies (1-year placebo-controlled) have shown that the number of patients losing >5% of body weight was increased compared to placebo. Mean percentage body weight loss with lorcaserin was -5.8% in first two studies and -4.5% in third study. In contrast, placebo patients who received lifestyle counseling lost -2.5% and -1.5% respectively. Overall, up to 47% of patients receiving medication lost more than 5% body weight.
Potential safety concerns with lorcaserin: initially there were concerns due to increased incidence of tumors in rats and possible valvulopathy (eg. mitral or aortic valve regurgitation). However, the FDA has concluded that it is unlikely that these are likely to occur in humans.
With phentermine/topiramate, two placebo-controlled studies have shown an increase in patients losing >5% of body weight compared to placebo. In the first study, the mean percentage change in body weight was -10.9% combination (dosage 15 mg/92 mg) compared with -1.6% for placebo. In the second study, this dosage led to a -9.8% reduction compared with -1.2% in placebo patients. Overall, up to 70% of patients receiving medication lost more than 5% body weight.
With regard to safety, it is known that topiramate is teratogenic and increases the risk of orofacial cleft. Due to this, approval for this combination requires a risk evaluation and mitigation strategy (REMS) which permits only specially-certified pharmacies to dispense along with formal training for prescribers. In addition, this combination has been associated with mildly increased heart rate. Due to favorable changes in blood pressure, the FDA concluded that this medication had a good benefit-risk balance. But, the manufacturer recommends against it use in patients with cardiac issues or cerebrovascular disease.
With both new medications, other safety concerns include the risk of increased psychiatric effects. In addition, specific recommendations include the following:
- Only recommended in adults with BMI ≥30 or adults with BMI ≥27 with at least one weight-related comorbidity
- With both medications, if weight loss not adequate after 12 weeks then discontinue medication. With lorcaserin, if weight loss is not ≥5%, then discontinue. With phentermine/topiramate, if weight loss is not ≥3% at 12 weeks (with 7.5 mg/46 mg), consider dosage increase and/or discontinuation.
Related blog entries:
- Eliminating sweetened beverages to help obesity | gutsandgrowth
- Weight of the Nation | gutsandgrowth
- Cardiovascular disease for the entire family | gutsandgrowth
- Psychology of obesity and food addiction | gutsandgrowth
- Staggering cost of obesity | gutsandgrowth
- Lower leptin with physical activity | gutsandgrowth